Amylyx Pharmaceuticals (AMLX) Amortizatization of Intangibles (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Amortizatization of Intangibles of $609000.0 for Q1 2026, down 64.24% year-over-year from $1.7 million in Q1 2025, and down 42.38% quarter-over-quarter from $1.1 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $609000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 64.24% year-over-year to $609000.0; the TTM figure through Mar 2026 stood at $4.4 million (down 50.63% YoY), while the FY2025 annual figure was $5.5 million, down 43.93% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $609000.0, down from $1.1 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $3.2 million in Q2 2024, with the low at -$2000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $1.8 million (2024), against an average of $1.6 million.
- The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles jumped 145250.0% in 2023, then sank 64.24% in 2026.
- Amylyx Pharmaceuticals' Amortizatization of Intangibles stood at $1.9 million in 2022, then surged by 38.28% to $2.6 million in 2023, then slumped by 30.37% to $1.8 million in 2024, then slumped by 40.98% to $1.1 million in 2025, then slumped by 42.38% to $609000.0 in 2026.
- Business Quant data shows AMLX's Amortizatization of Intangibles at $609000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | 1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Mn |
| Jun 30, 2026 | 1.22 Mn |
| Mar 31, 2026 | 609,000.00 |
| Mar 31, 2026 | 609,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | 2.31 Mn |
| Sep 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Mar 31, 2024 | 2.58 Mn |